Paclitaxel-Coated Devices’ Late Mortality Signal Not Well Understood, FDA Panel Hears

Following Wednesday’s debate on missing data necessary for paclitaxel-coated devices’ mortality assessments, the US Food and Drug Administration (FDA) advisory committee on Thursday offered recommendations on how to use what is in place to understand mortality signals.